Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 7/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.64 |
| ▸ | BLM | P54132 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | USP2 | O75604 | 3/20 | 0.64 |
| ▸ | RECQL | P46063 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.64 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.64 |
| ▸ | CSNK2A3 | Q8NEV1 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | MTOR | P42345 | 2/20 | 0.64 |
| ▸ | NSD2 | O96028 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350310 | 1.00 | CYP19A1 (0.68) | CYP19A1MEN1KMT2ATDP1BLM | |
| SCHEMBL11517791 | 1.00 | CYP19A1 (0.68) | CYP19A1MEN1KMT2ATDP1BLM | |
| Hydrochloric Acid SCHEMBL7204221 | 0.98 | CYP19A1 (0.66) | CYP19A1MEN1KMT2ATDP1BLM | |
| Hydrochloric Acid SCHEMBL4891873 | 0.97 | CYP19A1 (0.64) | CYP19A1MEN1KMT2ATDP1BLM | |
| SCHEMBL13194235 | 0.92 | CYP19A1 (0.59) | CYP19A1MEN1KMT2ATDP1BLM | |
| SCHEMBL19745828 | 0.92 | CSNK2A2 (0.61) | CYP19A1MEN1KMT2ATDP1BLM | |
| SCHEMBL10624602 | 0.91 | CYP19A1 (0.57) | CYP19A1MEN1KMT2ATDP1BLM | |
| SCHEMBL10523397 | 0.90 | MEN1 (0.75) | CYP19A1MEN1KMT2ATDP1BLM | |
| SCHEMBL10524500 | 0.90 | CYP19A1 (0.73) | CYP19A1MEN1KMT2ATDP1BLM | |
| SCHEMBL20334208 | 0.89 | MEN1 (0.58) | CYP19A1MEN1KMT2ATDP1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4820738-A | ANTITUMOR AGENTS; CHELATING AGENTS; GROWTH INHIBITORS; LEUKEMIA | AMERICAN CYANAMID COMPANY (US) | 1989-04-11 | — | — | US | claimed |
| US-4526989-A | And ascorbic acid salt | AMERICAN CYANAMID COMPANY (US) | 1985-07-02 | — | — | US | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2008042611-A2 | METHOD OF USING IL6 ANTAGONISTS WITH MITOXANTRONE FOR PROSTATE CANCER | CENTOCOR, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20080081041-A1 | Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer | NEMETH JEFFREY | 2008-04-03 | — | — | US | disclosed |
| US-5981600-A | Hydroxyanthraquinone derivatives | BAYKUT FIKRET (TR) | 1999-11-09 | — | — | US | disclosed |
| EP-0295316-B1 | Antitumor amino acid and peptide derivatives of 1,4-bis[ (aminoalkyl and hydroxyaminoalkyl)- amino]-5,8 dihydroxyanthraquinones | AMERICAN CYANAMID CO (US) | 1995-11-08 | — | — | EP | disclosed |
| EP-0217577-B1 | ANTIBODY COMPLEXES OF HAPTEN-MODIFIED DIAGNOSTIC OR THERAPEUTIC AGENTS | HYBRITECH INCORPORATED (US) | 1992-06-10 | — | — | EP | disclosed |
| EP-0489220-A1 | Cytotoxic N,N'-bis (succinyl-peptide-) derivatives of 1,4-bis (aminoalkyl)-5,8-dihydroxyanthraquinones and antibody conjugates thereof | AMERICAN CYANAMID COMPANY (US) | 1992-06-10 | — | — | EP | disclosed |
| EP-0170290-B1 | AMINO-ANTHRACENEDIONES-PLATINUM COMPLEXES USEFUL AS ANTI-CANCER COMPOUNDS | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1990-06-13 | — | — | EP | disclosed |
| US-4888137-A | CHELATING AGENTS, ANTICARCINOGENIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1989-12-19 | — | — | US | disclosed |
| EP-0295316-A2 | Antitumor amino acid and peptide derivatives of 1,4-bis[ (aminoalkyl and hydroxyaminoalkyl)- amino]-5,8 dihydroxyanthraquinones | AMERICAN CYANAMID COMPANY (US) | 1988-12-21 | — | — | EP | disclosed |
| US-4732893-A | ANTITUMOR AGENTS | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1988-03-22 | — | — | US | disclosed |
| US-4732970-A | Antitumor amino acid and peptide derivatives of 1,4-bis(aminoalkyl and hydroxy-aminoalkyl)amino)-5,8-dihydroxyanthraquinones | AMERICAN CYANAMID COMPANY (US) | 1988-03-22 | — | — | US | disclosed |
| EP-0217577-A2 | Antibody complexes of hapten-modified diagnostic or therapeutic agents | HYBRITECH INCORPORATED (US) | 1987-04-08 | — | — | EP | disclosed |
| EP-0182135-A2 | Novel bis-(substituted amino) anthraquinones | AMERICAN CYANAMID COMPANY (US) | 1986-05-28 | — | — | EP | disclosed |
| EP-0154117-A1 | Use of 1,4 bis(substituted) anthrachinones for the manufacture of immunosuppresiva | AMERICAN CYANAMID COMPANY (US) | 1985-09-11 | — | — | EP | disclosed |
| US-4540788-A | CHELATE COMPOUNDS, ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1985-09-10 | — | — | US | disclosed |
| EP-0131787-A2 | Novel Schiff bases of (aminoalkyl or substituted aminoalkyl)-amino-9,10-anthracenediones | AMERICAN CYANAMID COMPANY (US) | 1985-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081041-A1 | Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer | IL6, IL6ST, KLK3 | CYP19A1 178/4885MEN1 1315/4885KMT2A 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.